Tag: formulation

Navigating Risks of Poorly Justified Design Space During Validation Planning In the landscape of pharmaceutical manufacturing, the justification of design space during validation planning is critical. A poorly defined design…

Essential Playbook for Addressing Inadequate Control Strategies During Validation Planning In the fast-paced environment of pharmaceutical manufacturing, inadequate control strategies during validation planning can lead to significant regulatory hurdles, production…

Managing Yield Loss During Optimization in Development Studies: A Practical Playbook In pharmaceutical manufacturing, particularly during the early phases of formulation and process development, yield loss can significantly impact timelines,…

Strategies to Address Poor Justification of Design Space in Development Studies Ensuring that the design space is properly justified during the formulation and process development stages is essential for regulatory…

Managing Exceeding Limits of Process Variability During Regulatory Submission In today’s pharmaceutical landscape, ensuring compliance with regulatory expectations is paramount, particularly during critical stages of drug development. When process variability…

Framework for Improving Process Robustness Amidst Inadequate Control During Validation Planning In pharmaceutical manufacturing, a control strategy that is inadequate during validation planning can jeopardize product quality and compliance, leading…

Mitigating Risks of Poorly Justified Design Space During Pilot Scale Operations The pharmaceutical landscape is fraught with challenges, particularly during the pilot scale phase. One significant issue is the poorly…

Addressing Undefined CPPs During Validation Planning: An Actionable Playbook In the pharmaceutical manufacturing landscape, the identification and definition of Critical Process Parameters (CPPs) during validation planning is pivotal for ensuring…

Addressing Poorly Defined CPPs During Regulatory Submissions: An ICH Q8/Q11 Alignment Playbook In the fast-paced pharmaceutical landscape, poorly defined Critical Process Parameters (CPPs) during regulatory submissions pose significant risks, particularly…

Developing a Strategy for Non-Transferable Processes in Regulatory Submissions The pharmaceutical industry faces significant challenges when processes are deemed non-transferable during regulatory submissions, especially under guidelines set forth by ICH…

Mitigating Risks of Non-Transferable Processes During Validation Planning In the complex landscape of pharmaceutical manufacturing, one critical risk is the inability to transfer processes effectively during validation planning. This oversight…

Mitigating Regulatory Risks: Defining CPPs During Pilot Scale Development In the realm of pharmaceutical manufacturing, the definition of Critical Process Parameters (CPPs) during pilot scale activities often poses significant challenges.…